Financial Performance - Q4 total revenues increased by 11% year-over-year to $15.9 billion, with cloud services and license support revenues rising 14% to $11.7 billion[2][7] - Fiscal year 2025 total revenues reached $57.4 billion, up 8% in USD and 9% in constant currency[4][5] - Q4 GAAP net income was $3.4 billion, with non-GAAP net income at $4.9 billion, resulting in GAAP earnings per share of $1.19 and non-GAAP earnings per share of $1.70[3][7] - Total revenues for Q4 Fiscal 2025 reached $15.9 billion, an 11% increase compared to $14.2 billion in Q4 Fiscal 2024[17] - Operating income for Q4 Fiscal 2025 was $5.1 billion, reflecting a 9% increase from $4.7 billion in Q4 Fiscal 2024[17] - Net income for Q4 Fiscal 2025 was $3.4 billion, a 9% increase from $3.1 billion in Q4 Fiscal 2024[17] - Diluted earnings per share for Q4 Fiscal 2025 were $1.19, an 8% increase compared to $1.11 in Q4 Fiscal 2024[17] - Total revenues for fiscal 2025 reached $57.39 billion, representing a 8% increase compared to $52.96 billion in fiscal 2024[25] - Operating income was reported at $17.67 billion, with an operating margin of 31%, up from 29% in the previous year[25] - Net income for fiscal 2025 was $12.44 billion, a 19% increase from $10.47 billion in fiscal 2024[31] - Diluted earnings per share increased to $4.34, reflecting a 17% growth compared to $3.71 in fiscal 2024[25] Cloud Services Growth - Cloud Infrastructure revenue grew 52% in Q4 to $3.0 billion, while overall cloud revenue (IaaS plus SaaS) increased by 27% to $6.7 billion[7] - Oracle expects total cloud growth rates to exceed 40% in FY26, with Cloud Infrastructure growth projected to surpass 70%[6] - MultiCloud database revenue from Amazon, Google, and Azure grew 115% from Q3 to Q4, with expectations for continued triple-digit growth in FY26[6] - Cloud services and license support revenues for the year ended May 31, 2025, were $44.0 billion, a 12% increase from $39.4 billion in the previous year[22] - Cloud services revenue for Q4 FY2025 is expected to grow by 24% year-over-year, reaching $6.73 billion[35] - Constant currency revenue growth for cloud services is projected at 24% for FY2025, indicating robust demand[37] Operating Expenses and Cash Flow - Total operating expenses for the year ended May 31, 2025, were $39.7 billion, a 6% increase from $37.6 billion in the previous year[22] - Operating margin for Q4 Fiscal 2025 was 32%, compared to 33% in Q4 Fiscal 2024, reflecting a decrease of 67 basis points[17] - Operating cash flow for fiscal year 2025 was $20.8 billion, up 12% in USD[3] - The company reported a net cash provided by operating activities of $20.82 billion, an increase from $18.67 billion in fiscal 2024[31] - Capital expenditures for fiscal 2025 were $21.22 billion, significantly higher than $6.87 billion in fiscal 2024[31] - Cash and cash equivalents at the end of the period were $10.79 billion, up from $10.45 billion at the end of fiscal 2024[31] - Total current assets increased to $24.58 billion, compared to $22.55 billion in the previous year[29] - Total assets grew to $168.36 billion, up from $140.98 billion in fiscal 2024[29] Stock-Based Compensation and Non-GAAP Measures - Total stock-based compensation for Q4 Fiscal 2025 was $1.3 billion, up from $1.0 billion in Q4 Fiscal 2024[18] - Stock-based compensation expenses rose to $4.67 billion, compared to $3.97 billion in the previous year[26] - The company utilizes non-GAAP financial measures to provide a clearer understanding of past performance and future results, excluding stock-based compensation and acquisition-related expenses[40] - Stock-based compensation expenses are excluded from non-GAAP measures, although they are considered a key incentive for employees and will recur in future periods[40] - Amortization of intangible assets is excluded from non-GAAP measures due to its inconsistent nature and impact from acquisitions, contributing to future revenues[41] - Acquisition-related expenses include personnel costs and business combination adjustments, which are excluded from non-GAAP measures to provide clarity on operating expenses[42] - Restructuring expenses, such as employee severance, are also excluded from non-GAAP measures, reflecting costs that may recur with future acquisitions[42] Future Outlook and Strategic Plans - The company plans to continue expanding its market presence through new product developments and strategic acquisitions[35] - Oracle has 23 MultiCloud datacenters live and plans to build 47 more over the next 12 months[6] - The Americas region generated $10.0 billion in revenue for Q4 FY2025, marking a 36.3% increase year-over-year[36]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 3, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-38026 J.Jill, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 3, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 0-23071 THE CHILDREN'S PLACE, INC. (Exact name of registrant as specified in its charter) D ...

Revenue Performance - Total revenues decreased by $976,182, or 43.47%, to $1,269,373 for the three months ended September 30, 2024, from $2,245,555 for the same period in 2023[226] - Revenues from the nutraceutical business decreased by $970,183, or 43.32%, to $1,269,373 for the three months ended September 30, 2024, primarily due to cash constraints affecting the ability to purchase raw materials[227] - Total revenues decreased by $2,560,296, or 49.37%, to $2,626,080 for the nine months ended September 30, 2024, from $5,186,376 in the same period of 2023[240] - Revenues from the nutraceutical business decreased by $2,198,941, or 45.57%, to $2,625,965 for the nine months ended September 30, 2024, primarily due to cash constraints[242] - The digital marketing business did not generate any revenues for the three months ended September 30, 2024, compared to $5,999 for the same period in 2023[228] Profitability and Loss - Gross profit increased to $518,056, representing 40.81% of total revenues for the three months ended September 30, 2024, compared to 37.25% for the same period in 2023[226] - Operating loss for the three months ended September 30, 2024, was $(1,204,102), or (94.86)%, compared to $(2,916,431), or (129.88)%, for the same period in 2023[226] - Net loss for the three months ended September 30, 2024, was $(3,235,878), or (254.92)%, compared to $(4,344,107), or (193.45)%, for the same period in 2023[226] - Gross profit decreased by $318,331, or 38.06%, to $518,056 for Q3 2024 from $836,387 in Q3 2023, with gross profit as a percentage of revenues at 40.81% versus 37.25%[232] - Net loss for Q3 2024 was $3,235,878, a decrease of $1,108,229 or 25.51% from a net loss of $4,344,107 in Q3 2023[239] - Net loss for the nine months ended September 30, 2024 was $8,343,073, a decrease of $4,505,346, or 35.07%, from a net loss of $12,848,419 in the same period of 2023[255] Expenses Management - The total cost of revenues decreased by $657,851, or 46.68%, to $751,317 for the three months ended September 30, 2024, from $1,409,168 for the same period in 2023[229] - General and administrative expenses decreased to $428,554, or 33.76% of revenues, for the three months ended September 30, 2024, from $1,174,348, or 52.30% of revenues, for the same period in 2023[226] - Compensation expenses decreased to $570,126, or 44.91% of revenues, for the three months ended September 30, 2024, from $1,907,195, or 84.93% of revenues, for the same period in 2023[226] - General and administrative expenses decreased by $745,793, or 63.51%, to $428,554 for Q3 2024 from $1,174,348 in Q3 2023, representing 33.76% of revenues compared to 52.30%[233] - Compensation expenses decreased by $1,337,069, or 70.11%, to $570,126 for Q3 2024 from $1,907,195 in Q3 2023, with a percentage of revenues at 44.91% versus 84.93%[234] Financial Position and Cash Flow - The company reported a working capital deficiency of $8.2 million as of September 30, 2024, raising substantial doubt about its ability to continue as a going concern[257] - Net cash used in operating activities decreased to $516,784 for the nine months ended September 30, 2024, compared to $5,952,710 for the same period in 2023[260] - Net cash provided by financing activities was $403,069 for the nine months ended September 30, 2024, down from $5,897,604 in 2023[262] - Total outstanding debt as of September 30, 2024, amounted to $3,239,177, with current debt at $2,221,163[265] - The company is dependent on raising additional capital through common and preferred stock placements and debt financing to fund planned expenditures over the next 12 months[258] - Cash and cash equivalents at the end of the period were $35,608, compared to $5,684 at the end of the same period in 2023[260] - The company had net cash used in investing activities of $5,343 for the nine months ended September 30, 2024, which was entirely for additions to property and equipment[261] - The company has no off-balance sheet arrangements that could affect its financial condition[267] - Management believes that currently available resources will not be sufficient to fund planned expenditures, indicating potential financial challenges ahead[258] Strategic Initiatives - The company continues to execute a buy-and-build strategy with a focus on acquiring profitable companies to drive growth and earnings[214]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 3, 2025 OR 12420 Stonebridge Road, Roanoke, Indiana 46783 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Exhibit 99.1 DoubleVerify Reports First Quarter 2025 Financial Results Increased Revenue by 17% Year-over-Year to $165.1 Million Increased First Quarter Activation Revenue by 20% and Supply-Side Revenue by 35% Year-over-Year Achieved Net Income of $2.4 Million and Adjusted EBITDA of $44.7 Million, representing a 27% Adjusted EBITDA margin NEW YORK – May 8, 2025 – DoubleVerify ("DV") (NYSE: DV), the leading software platform for digital media measurement, data, and analytics, today announced financial result ...

First quarter consolidated net revenues totaled $51.7 million Financial condition remains strong with $86 million in liquidity and no debt FORT WAYNE, Ind., June 11, 2025 – Vera Bradley, Inc. (Nasdaq: VRA) today announced its financial results for the first quarter of the fiscal year ending January 31, 2026 ("Fiscal 2026"). First Quarter Comments VERA BRADLEY ANNOUNCES FIRST QUARTER FISCAL YEAR 2026 RESULTS For the current year first quarter, Vera Bradley, Inc.'s net loss from continuing operations totaled ...

Revenue and Financial Performance - Rafael Holdings reported a product revenue of approximately $243 thousand for the three and nine months ended April 30, 2025, compared to $0 for the same periods in 2024, primarily due to the inclusion of Cyclo's revenue following the merger[374]. - Infusion Technology segment revenue decreased by 84% to $42,000 for the three months ended April 30, 2025, compared to $262,000 in the same period of 2024[378]. - Real Estate segment rental revenue increased by 4% to $49,000 for the three months ended April 30, 2025, compared to $47,000 in the same period of 2024[382]. - Consolidated loss from operations improved by 94% to $5.9 million for the three months ended April 30, 2025, compared to a loss of $93.2 million in the same period of 2024[383]. - Interest income for the three months ended April 30, 2025, was $0.5 million, consistent with the same period in 2024[384]. - Unrealized loss on investment in Cyclo was $1.4 million for the three months ended April 30, 2025, a decrease of 68% compared to a loss of $4.4 million in the same period of 2024[386]. - Other income, net was $0.2 million for the three months ended April 30, 2025, attributed to gains from asset sales, compared to no other income in the same period of 2024[391]. - Revenue from tenants located in Israel represented 41% of consolidated revenues for the nine months ended April 30, 2025, with the entirety of these revenues in currencies other than the U.S. Dollar[413]. Expenses and Impairments - The company's general and administrative expenses increased by 90% to $3,102 thousand for the three months ended April 30, 2025, compared to $1,636 thousand in the same period of 2024, largely due to legal and professional fees associated with the Cyclo merger[375]. - Research and development expenses rose by 148% to $3,003 thousand for the three months ended April 30, 2025, compared to $1,212 thousand in the same period of 2024, driven by Cyclo's inclusion and ongoing activities at LipoMedix and Cornerstone[376]. - The Infusion Technology segment recorded a goodwill impairment charge of $3.1 million during the nine months ended April 30, 2025, indicating a significant decline in asset value[379]. - The company recorded an impairment charge of $3.1 million related to the Infusion Technology segment's goodwill during the nine months ended April 30, 2025[407]. Cash and Assets - Cash and cash equivalents increased by 1,318% to $37.9 million as of April 30, 2025, compared to $2.7 million on July 31, 2024[393]. - Total assets increased by 12% to $108.1 million as of April 30, 2025, compared to $96.8 million on July 31, 2024[393]. - As of April 30, 2025, the company held cash and cash equivalents of approximately $37.9 million, expected to meet obligations for at least the next 12 months[394]. - Cash used in operating activities increased by $3.6 million, from $4.9 million for the nine months ended April 30, 2024, to $8.5 million for the nine months ended April 30, 2025, primarily due to increased operating activity following the Cyclo Merger[395]. - Cash provided by investing activities for the nine months ended April 30, 2025, included proceeds of $80.7 million from sales and maturities of available-for-sale securities[396]. - Cash used in financing activities for the nine months ended April 30, 2025, included a payment for taxes related to shares withheld for employee taxes of $108 thousand[398]. - Cash provided by financing activities for the nine months ended April 30, 2024, was primarily related to proceeds from the sale of RMD membership units of $0.9 million[399]. Clinical and Product Development - The loss from operations for the Healthcare segment decreased by 94% to $5,884 thousand for the three months ended April 30, 2025, compared to a loss of $92,782 thousand in the same period of 2024[372]. - Rafael Holdings holds a 95% interest in LipoMedix, which has completed various clinical stages of its product candidate, Promitil®, treating a total of 149 patients[364]. - The company intends to fund the TransportNPC Phase 3 clinical trial for Trappsol® Cyclo™ with results expected later this month, which will inform the decision on filing a New Drug Application (NDA)[363]. - Following the merger with Cyclo, Rafael Holdings is focusing on Trappsol Cyclo™ as its lead clinical program, evaluating its operating entities to align resources with core assets[361]. - Rafael Medical Devices received FDA clearance for the VECTR System, which is intended for minimally invasive surgeries, marking a significant milestone for the company[369]. - As of April 30, 2025, Rafael Holdings holds a 67% interest in Cornerstone Pharmaceuticals following a restructuring, which has become a consolidated subsidiary[368]. Inventory and Dividends - The company did not have any inventory as of July 31, 2024, and recognized inventory acquired in the Cyclo Merger at its fair value of $270 thousand[410]. - The company determined no reserve for obsolete inventory was necessary as of April 30, 2025[410]. - The company does not anticipate paying dividends on common stock until achieving sustainable profitability and retaining certain minimum cash reserves[399].

Financial Performance - Net sales for the 13 weeks ended May 4, 2025, were $3,116.0 million, an increase of 8.3% compared to $2,877.7 million for the same period in 2024[90]. - Net income decreased to $62.4 million, down 6.7% from $66.9 million in the prior year, resulting in a net margin of 2.0%[90]. - Adjusted EBITDA rose to $192.7 million, reflecting an 18.3% increase from $162.9 million in the previous year, with an adjusted EBITDA margin of 6.2%[90]. - Adjusted net income for the quarter was $148.9 million, an 8.6% increase from $137.1 million in the prior year[99]. - Adjusted basic earnings per share increased by 12.5% to $0.36, while adjusted diluted earnings per share rose by 12.9% to $0.35[99]. Customer Metrics - Active customers increased by 3.8% to 20.756 million, compared to 19.988 million in the prior year[90]. - Net sales per active customer grew by 3.7% to $583, up from $562 in the same period last year[90]. - Autoship customer sales reached $2,562.7 million, a 14.8% increase from $2,232.9 million, representing 82.2% of net sales[90]. - Active customers increased by 3.8% to 20.8 million, contributing to net sales growth of 8.3%, reaching $3.1 billion compared to $2.9 billion in the prior year[119]. - Net sales per active customer rose by $21 to $583, driven by growth in healthcare, specialty, and hardgoods businesses[119]. Expenses and Costs - Cost of goods sold increased by 8.3% to $2.2 billion, consistent with the increase in net sales, reflecting higher product and shipping supply costs[120]. - Gross profit for the period was $923.8 million, an increase of 8.2%, with a gross margin of 29.6%, slightly down from 29.7% in the previous year[121]. - Selling, general and administrative expenses rose by 8.4% to $653.1 million, primarily due to expansion costs in fulfillment operations and pharmacy networks[122]. - Advertising and marketing expenses increased by 3.7% to $193.8 million, with expectations for these expenses to be approximately 6.7 to 6.8 percent of net sales for the fiscal year[124]. Cash Flow and Investments - Free cash flow decreased to $48.7 million, down 7.4% from $52.6 million in the previous year[90]. - Free cash flow for the thirteen weeks ended May 4, 2025, was $48.7 million, a decrease from $52.6 million for the same period in 2024, with net cash provided by operating activities at $86.4 million[104]. - Net cash provided by operating activities for the thirteen weeks ended May 4, 2025, was $86.4 million, an increase from $81.9 million for the same period in 2024[129][130]. - Net cash used in investing activities was $41.2 million for the thirteen weeks ended May 4, 2025, primarily for capital expenditures of $37.7 million related to expanding operations[132]. - Net cash used in financing activities was $25.0 million for the thirteen weeks ended May 4, 2025, mainly for repurchases of common stock totaling $23.1 million[134]. Financial Position - Cash and cash equivalents totaled $616.4 million as of May 4, 2025, reflecting an increase of $20.6 million from February 2, 2025[127]. - The company has a senior secured asset-based credit facility with a borrowing capacity of $782.8 million as of May 4, 2025, with no outstanding borrowings[136]. - The Board of Directors authorized a share repurchase program of up to $500 million, with $383.5 million remaining available for repurchase as of May 4, 2025[137][138]. - The ABL Credit Facility matures on April 1, 2030, and allows for incremental commitments of up to $250 million[136]. Operational Adjustments - The company continues to adapt its logistics and supply chain processes in response to evolving macroeconomic conditions, including inflation and high interest rates[86]. - The company is modernizing its finance information technology architecture to enhance scalability and analytical capabilities, expected to conclude by the end of the 2025 fiscal year[123]. - Non-cash adjustments in operating activities included share-based compensation expense of $74.5 million and depreciation and amortization expense of $30.0 million for the thirteen weeks ended May 4, 2025[130]. - Working capital changes for the thirteen weeks ended May 4, 2025, resulted in a cash decrease of $88.8 million, primarily due to a decrease in accrued expenses and an increase in accounts receivable[130]. Previous Year Comparison - The company reported a net income of $62.4 million for the thirteen weeks ended May 4, 2025, compared to $66.9 million for the same period in 2024[130][131]. - Interest income decreased by $11.3 million to $3.2 million, attributed to lower income from marketable securities[125]. - The company experienced a significant cash inflow of $505.7 million from investing activities for the thirteen weeks ended April 28, 2024, primarily from the maturities of marketable securities[133].

"We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48- week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, "We have enhanced our financial position with the closing of a $25 million rights of ...